We more generally hypothesize that there may be signaling differences for PLCB4 mutant melanoma and for other mutant forms of GNAQ/11 and of CYSLTR2. Additional characterization of signaling by other mutants found in UM appears to be an important area for more experimental investigation that our model-based study has motivated. This evidence concerns the gene PLCB4 and melanoma.